Overview

A Study of JNJ-77474462 in Healthy Participants

Status:
Completed

Trial end date:
2021-05-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the pharmacokinetics (PK) of JNJ-77474462 after single subcutaneous (SC) or intravenous (IV) administrations and the effect of formulation concentrations on PK of JNJ-77474462 in healthy participants.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Interleukin 1 Receptor Antagonist Protein